ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Celltrion

  • 182,500.00 KRW
  • +2,000.00
  • +1.11%
  • South Korea
    Jul 18, 2019
  • Ticker
    KRX(068270)
  • Prev. close
    180,500
  • Market cap (KRW)
    23,163.39B
  • Market cap (USD)
    19,649.98M
  • Shares
    128.32M

Company Background

Celltrion is a South Korean pharmaceutical venture that develops "biosimilars" -- generic equivalents of biopharmaceuticals -- using microorganisms and animal cells. Remsima, a biosimilar treatment for rheumatoid arthritis, has been approved for sale in South Korea, Japan, Europe, Australia and Latin America.

Founded in 2002, Celltrion started out as a contract manufacturer for Western drug companies. It moved into biosimilars in 2008. The company's plants in South Korea can produce 200,000 liters of protein drugs per year.

In addition to well-known treatments Remsima and breast cancer drug Herzuma, the company develops and markets one to two new products a year. Celltrion plans to focus on developed markets, including Japan, the U.S. and Europe, where demand for biosimilars is growing rapidly.

Because Celltrion is a research and development-oriented company, its operating profit margin has remained high. It is one of the top companies on the Kosdaq market for startups in terms of market capitalization.

Business Summary

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Financial Highlights

Dec 2018 KRWUSD
Revenue982,074.95M892.37M
Gross Profit541,284.44M491.84M
Operating income338,291.33M307.39M
Income before tax317,725.82M288.70M
Net income261,841.76M237.92M
EBITDA465,057.52M422.58M
Diluted EPS2,040.731.85
Dividends Per Share00
Total Assets3,628.33B3,251.78M
Total liabilities992,561.59M889.55M
Total equity2,524.02B2,262.07M
Operating cash flow372,074.18M338.09M
Currency in KRWCurrency in USD

Historical Data

 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 471,045.51M 603,412.76M 670,580.96M 949,079.96M 982,074.95M
Gross Profit 333,937.37M 361,042.87M 388,407.95M 685,318.99M 541,284.44M
Operating income 201,417.00M 258,922.92M 249,614.31M 507,771.41M 338,291.33M
Income before tax 149,377.60M 162,901.39M 228,752.75M 491,503.19M 317,725.82M
Net income 112,676.33M 154,089.61M 177,994.50M 382,467.03M 261,841.76M
EBITDA 277,695.81M 341,097.00M 338,289.64M 605,721.68M 465,057.52M
Diluted EPS 940.28 1,246.77 1,397.53 2,934.31 2,040.73
Dividends Per Share 0 0 0 0 0
Total Assets 2,394.26B 2,825.98B 3,117.56B 3,410.79B 3,628.33B
Total liabilities 1,045.80B 1,015.16B 914,607.61M 975,863.55M 992,561.59M
Total equity 1,247.39B 1,694.23B 2,053.63B 2,308.89B 2,524.02B
Operating cash flow 111,000.58M 45,199.75M 230,062.47M 482,870.20M 372,074.18M
 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 447.48M 533.14M 577.99M 839.51M 892.37M
Gross Profit 317.23M 318.99M 334.77M 606.20M 491.84M
Operating income 191.34M 228.77M 215.14M 449.15M 307.39M
Income before tax 141.90M 143.93M 197.16M 434.76M 288.70M
Net income 107.03M 136.14M 153.41M 338.31M 237.92M
EBITDA 263.80M 301.37M 291.58M 535.79M 422.58M
Diluted EPS 0.89 1.10 1.20 2.59 1.85
Dividends Per Share 0 0 0 0 0
Total Assets 2,178.28M 2,410.12M 2,581.19M 3,186.01M 3,251.78M
Total liabilities 951.46M 865.77M 757.25M 911.55M 889.55M
Total equity 1,134.87M 1,444.91M 1,700.31M 2,156.73M 2,262.07M
Operating cash flow 105.44M 39.93M 198.29M 427.12M 338.09M

Valuation Measures

Dec 2018
PER108.06
ROA7.43%
ROE10.83%
Operating margin34.44%
Profit margin26.66%

Key executives

  • Chief Executive Officer & Director: Wu-Sung Ki
  • Head-Legal & Compliance Support: Sung-Han Lee
  • Vice President: Sang-Joon Lee
  • Vice President: Jung-Won Yoon
  • Executive Board Member: Yoon-Mo Koo

Shareholders

  • SEO JUNG-JIN (22.1%)
  • Temasek Holdings Pte Ltd. (Investment Management) (9.5%)
  • National Pension Service of Korea (6.0%)
  • The Vanguard Group, Inc. (2.0%)
  • BlackRock Fund Advisors (1.7%)
  • Baillie Gifford & Co. (1.4%)
  • Samsung Asset Management Co., Ltd. (0.9%)
  • Mirae Asset Global Investments Co., Ltd. (0.8%)
  • Celltrion, Inc. (0.7%)
  • Norges Bank Investment Management (0.7%)

Contact Details

Related Companies

  • Celltrion Inc. Employee Stock Ownership ASSN.
  • Celltrion Pharm Inc.

Competitors

  • Novartis AG
  • Biocon Limited
  • Samsung BioLogics Co., Ltd.
  • Pfizer Inc.
  • Mylan N.V.
  • Amgen Inc.
  • Mabion SA
  • Allergan plc
  • EPIRUS Biopharmaceuticals, Inc.
  • Reyon Pharmaceutical Co., Ltd.
  • Binex Co., Ltd
  • BCWORLDPHARM. Co., Ltd.
  • BioInvent International AB
  • Momenta Pharmaceuticals, Inc.
  • ALTEOGEN Inc.
  • Dexter Studios Co., Ltd.
Last Updated on 18 Jul, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media